Edge Rankings

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Royalty Pharma Stock Price, Quotes and Forecasts | NASDAQ:RPRX | Benzinga

Q: What sector and industry does Royalty Pharma (RPRX) operate in?

Royalty Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Explore Royalty Pharma stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for RPRX.

Open	-
Close	-
Volume / Avg.	0 / 4.08M
Day Range	- - -
52 Wk Range	24.05 - 34.20
Market Cap	$14.72B
P/E Ratio	17.73
Dividend Yield	2.60%
Exchange	NASDAQ
RSI	77
Short Interest	3.67%
Days to Cover	3.87

Recent News

Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to $250 million in R&D funding from Royalty Pharma.

Vandana Singh

US Stocks Dip As Powell Stays Cautious, Intel Climbs, Tesla Sinks To 11-Week Low: What's Driving Markets Tuesday?

U.S.

Piero Cingari

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Oct 24

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	-
Close	-
Volume / Avg.	0 / 4.08M
Day Range	- - -
52 Wk Range	24.05 - 34.20
Market Cap	$14.72B
P/E Ratio	17.73
Dividend Yield	2.60%
Exchange	NASDAQ
RSI	77
Short Interest	3.67%
Days to Cover	3.87

About Royalty Pharma plc

Sector

Health Care

Industry

Pharmaceuticals

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of ...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Royalty Pharma (RPRX) stock?

You can purchase shares of Royalty Pharma (NASDAQ:RPRX) through any online brokerage.

View our list of the best stock brokerages

Who are Royalty Pharma (RPRX) competitors?

Other companies in Royalty Pharma’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Verona Pharma (NASDAQ:VRNA) and Novartis (NYSE:NVS).

What is the forecast, or price target, for Royalty Pharma (RPRX) stock?

Royalty Pharma has a consensus price target of $45.38.

What is the current price for Royalty Pharma (RPRX)?

The stock price for Royalty Pharma (NASDAQ: RPRX) is $33.97 last updated March 3, 2025 at 7:53 PM EST.

Does Royalty Pharma (RPRX) pay a dividend?

A quarterly cash dividend of 0.22 per share of Class A Common Stock. The quarterly cash dividend was payable on March 10, 2025 to stockholders of record on February 21, 2025.

When is Royalty Pharma (NASDAQ:RPRX) reporting earnings?

Royalty Pharma’s Q1 earnings are confirmed for Thursday, May 8, 2025.

Is Royalty Pharma (RPRX) going to split?

There is no upcoming split for Royalty Pharma.

What sector and industry does Royalty Pharma (RPRX) operate in?

Royalty Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Comments

Royalty Pharma Stock Price, Quotes and Forecasts

Royalty Pharma (RPRX) Forecast